

## Reminder: Invitation to Roche's Full Year Results 2019 Presentation



Roche will publish its Full Year Results for 2019 prior to the opening of the Swiss Stock Exchange on Thursday, 30 January 2020.

**7:00 CET / 6:00 GMT / 1:00 AM EST / 10:00 PM PST (evening before)**

Release will be e-mailed and posted on the Roche IR website > [click here](#).  
Presentation slides will be posted on the Roche IR website > [click here](#).

We would like to invite all interested parties to participate or dial in to the event outlined below.

### **Thursday, 30 January 2020, London**

The Full Year Presentation will be held at the London Stock Exchange, 10 Paternoster Square, London EC4M 7LS > [map](#)

#### **Presenters:**

- Severin Schwan, CEO Roche Group
- Bill Anderson, CEO Roche Pharmaceuticals
- Thomas Schinecker, CEO Roche Diagnostics
- Alan Hippe, Chief Financial and IT Officer

**Meeting information:**

30 January 2020

Time (GMT):

14:30 Registration

15:00 Meeting starts

17:00 Meeting ends, followed by a buffet reception

**To register for the event**, please follow the > [link](#)

Following the event we would also like to invite you to drinks and canapés to give you the opportunity to speak to management more informally.

Please make sure you have government recognised photographic identification with you, i.e. a passport, and allow enough time to go through the London Stock Exchange security check.

**Live video webcast**

This presentation can also be accessed through a live video webcast: > [click here](#).

**Access to Conference Call (pre-registration required)**

You will receive phone numbers, passcode and your personal PIN to direct access the conference call by pre-registering here.

Should you have any issues with the registration, please dial the following numbers on the day of the conference call 10-15 minutes prior to conference start.

+41 (0) 58 310 5000 (Europe and ROW) or

+44 (0) 207 107 0613 (UK) or

+1 (1) 631 570 5613 (USA)

**Replay**

A replay of the video webcast will be available on demand on the Roche [website](#).

Best regards,

Karl Mahler

Head of Investor Relations and Roche Group Planning

**Roche Investor Relations**

Dr. Karl Mahler

Phone: +41 61 68-78503

e-mail: [karl.mahler@roche.com](mailto:karl.mahler@roche.com)

Jon Kaspar Bayard

Phone: +41 61 68-83894

e-mail: [jon\\_kaspar.bayard@roche.com](mailto:jon_kaspar.bayard@roche.com)

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: [sabine.borngraeber@roche.com](mailto:sabine.borngraeber@roche.com)

Dr. Bruno Eschli

Phone: +41 61 68-75284

e-mail: [bruno.eschli@roche.com](mailto:bruno.eschli@roche.com)

Dr. Birgit Masjost  
Phone: +41 61 68-84814  
e-mail: [birgit.masjost@roche.com](mailto:birgit.masjost@roche.com)

Dr. Gerard Tobin  
Phone: +41 61 68-72942  
e-mail: [gerard.tobin@roche.com](mailto:gerard.tobin@roche.com)

**Investor Relations North America**

Loren Kalm  
Phone: +1 650 225 3217  
e-mail: [kalm.loren@gene.com](mailto:kalm.loren@gene.com)

Dr. Lisa Tuomi  
Phone: +1 650 467 8737  
e-mail: [tuomi.lisa@gene.com](mailto:tuomi.lisa@gene.com)